A phase II clinical study of suramin in combination with mitomycin C in patients with non small cell lung cancer

Bernardo Leon Rapoport; Geoffrey Falkson; Stephen Maxted Ansell; Barend Petrus Lotz; Magriet de Wet

doi:10.1016/0169-5002(91)90029-6

A phase II clinical study of suramin in combination with mitomycin C in patients with non small cell lung cancer

Bernardo Leon Rapoport, Geoffrey Falkson, Stephen Maxted Ansell, Barend Petrus Lotz, Magriet de Wet

Hematology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Fifteen patients with advanced non small cell lung cancer (NSCLC) were entered into a study of suramin given as a 4 h infusion of 350 mg/m² per day for 5 days, followed by 350 mg/m² weekly from day 14, plus mitomycin C (MMC) 12 mg/m² given every 5 weeks starting on day 14. No responses were seen in the 15 patients treated with suramin and MMC. One patient experienced lethal toxic epidermonecrolysis. Other toxicities were mild and consisted of a maculopapular skin rash in 5 patients, temporary sensory peripheral neuropathy in 4 patients and proteinuria in 2 patients. Mild nausea and vomiting occurred in 3, mild leucopenia or thrombocytopenia in 2 and moderate infection in 3 patients. The median time to treatment failure was 28 days. The median survival time was 155 days. Suramin in combination with MMC has acceptable toxicity but showed no therapeutic activity in patients with NSCLC in this trial.

Original language	English (US)
Pages (from-to)	323-328
Number of pages	6
Journal	Lung Cancer
Volume	7
Issue number	5
DOIs	https://doi.org/10.1016/0169-5002(91)90029-6
State	Published - Oct 1991

Keywords

Mitomycin-C
Non Small Cell Lung Cancer
Suramin

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.1016/0169-5002(91)90029-6

Cite this

@article{2034215047f8475ba1b6a5be17ebce38,

title = "A phase II clinical study of suramin in combination with mitomycin C in patients with non small cell lung cancer",

abstract = "Fifteen patients with advanced non small cell lung cancer (NSCLC) were entered into a study of suramin given as a 4 h infusion of 350 mg/m2 per day for 5 days, followed by 350 mg/m2 weekly from day 14, plus mitomycin C (MMC) 12 mg/m2 given every 5 weeks starting on day 14. No responses were seen in the 15 patients treated with suramin and MMC. One patient experienced lethal toxic epidermonecrolysis. Other toxicities were mild and consisted of a maculopapular skin rash in 5 patients, temporary sensory peripheral neuropathy in 4 patients and proteinuria in 2 patients. Mild nausea and vomiting occurred in 3, mild leucopenia or thrombocytopenia in 2 and moderate infection in 3 patients. The median time to treatment failure was 28 days. The median survival time was 155 days. Suramin in combination with MMC has acceptable toxicity but showed no therapeutic activity in patients with NSCLC in this trial.",

keywords = "Mitomycin-C, Non Small Cell Lung Cancer, Suramin",

author = "Rapoport, {Bernardo Leon} and Geoffrey Falkson and Ansell, {Stephen Maxted} and Lotz, {Barend Petrus} and {de Wet}, Magriet",

year = "1991",

month = oct,

doi = "10.1016/0169-5002(91)90029-6",

language = "English (US)",

volume = "7",

pages = "323--328",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "5",

}

TY - JOUR

T1 - A phase II clinical study of suramin in combination with mitomycin C in patients with non small cell lung cancer

AU - Rapoport, Bernardo Leon

AU - Falkson, Geoffrey

AU - Ansell, Stephen Maxted

AU - Lotz, Barend Petrus

AU - de Wet, Magriet

PY - 1991/10

Y1 - 1991/10

N2 - Fifteen patients with advanced non small cell lung cancer (NSCLC) were entered into a study of suramin given as a 4 h infusion of 350 mg/m2 per day for 5 days, followed by 350 mg/m2 weekly from day 14, plus mitomycin C (MMC) 12 mg/m2 given every 5 weeks starting on day 14. No responses were seen in the 15 patients treated with suramin and MMC. One patient experienced lethal toxic epidermonecrolysis. Other toxicities were mild and consisted of a maculopapular skin rash in 5 patients, temporary sensory peripheral neuropathy in 4 patients and proteinuria in 2 patients. Mild nausea and vomiting occurred in 3, mild leucopenia or thrombocytopenia in 2 and moderate infection in 3 patients. The median time to treatment failure was 28 days. The median survival time was 155 days. Suramin in combination with MMC has acceptable toxicity but showed no therapeutic activity in patients with NSCLC in this trial.

AB - Fifteen patients with advanced non small cell lung cancer (NSCLC) were entered into a study of suramin given as a 4 h infusion of 350 mg/m2 per day for 5 days, followed by 350 mg/m2 weekly from day 14, plus mitomycin C (MMC) 12 mg/m2 given every 5 weeks starting on day 14. No responses were seen in the 15 patients treated with suramin and MMC. One patient experienced lethal toxic epidermonecrolysis. Other toxicities were mild and consisted of a maculopapular skin rash in 5 patients, temporary sensory peripheral neuropathy in 4 patients and proteinuria in 2 patients. Mild nausea and vomiting occurred in 3, mild leucopenia or thrombocytopenia in 2 and moderate infection in 3 patients. The median time to treatment failure was 28 days. The median survival time was 155 days. Suramin in combination with MMC has acceptable toxicity but showed no therapeutic activity in patients with NSCLC in this trial.

KW - Mitomycin-C

KW - Non Small Cell Lung Cancer

KW - Suramin

UR - http://www.scopus.com/inward/record.url?scp=0025988745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025988745&partnerID=8YFLogxK

U2 - 10.1016/0169-5002(91)90029-6

DO - 10.1016/0169-5002(91)90029-6

M3 - Article

AN - SCOPUS:0025988745

SN - 0169-5002

VL - 7

SP - 323

EP - 328

JO - Lung Cancer

JF - Lung Cancer

IS - 5

ER -

A phase II clinical study of suramin in combination with mitomycin C in patients with non small cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this